Differential expression of PD-1/PD-L1 axis in mediastinal lymph nodes of experimental and human lung fibrosis

Karampitsakos, Theodoros; Chrysikos, Serafeim; Galaris, Apostolos; Vavmakaris, Ioannis; Papaioannou, Ourania; Katsaras, Matthaios; Papalexatos, Dionysios; Bouros, Evangelos; Anagnostopoulos, Aris; Dimakou, Katerina; Manali, Effrosyni D.; Papiris, Spyridon; Bouros, Demosthenes; Bakakos, Petros; Aidinis, Vassilis; Τzouvelekis, Αrgyris

doi:10.1183/23120541.lsc-2022.54

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, pneumonitis in patients with IPF might be fatal [42,91]. Lower doses might be the key to target PD-1/PD-L1 axis, which seems to have a role in lung fibrosis as well, and concomitantly reduce the likelihood of adverse events [95][96][97][98][99][100][101]. Multidisciplinary discussion for the risk-benefit ratio on a case-by-case basis is suggested.…”

Section: Which Chemotherapy/ Immunotherapy Regimens Are Beneficial Fo...mentioning

confidence: 99%

Management of patients with idiopathic pulmonary fibrosis and lung cancer: challenges in clinical practice

Karampitsakos

Sampsonas

Herazo-Maya

et al. 2023

Current Opinion in Pulmonary Medicine

Self Cite

View full text Add to dashboard Cite

Purpose of review Idiopathic pulmonary fibrosis (IPF) is the nonmalignant, chronic lung disease with the worst prognosis. Prevalent comorbidities including lung cancer exert a negative impact on patients’ survival. However, there is considerable lack of knowledge on the diagnostic and therapeutic management of patients diagnosed with both clinical entities. This review article presents the main challenges in the management of patients with IPF and lung cancer and highlights future perspectives. Recent findings Recent registries for patients with IPF demonstrated that approximately 10% of patients developed lung cancer. Importantly, incidence of lung cancer was increasing remarkably over time in patients with IPF. Patients with IPF and otherwise technically operable lung cancer who underwent surgical resection had improved survival compared with those who did not undergo surgery. However, specific precautions perioperatively are crucial. Finally, the first randomized-controlled, phase 3 trial (J-SONIC trial) showed no significant difference in exacerbation-free survival for chemotherapy-naive patients with IPF and advanced nonsmall cell lung cancer that were allocated to receive carboplatin and nab-paclitaxel every 3 weeks with or without nintedanib. Summary Lung cancer is prevalent in IPF. Management of patients with IPF and lung cancer is challenging. A consensus statement aiming to attenuate confusion is greatly anticipated.

show abstract

Section: Which Chemotherapy/ Immunotherapy Regimens Are Beneficial Fo...mentioning

confidence: 99%

Management of patients with idiopathic pulmonary fibrosis and lung cancer: challenges in clinical practice

Karampitsakos

Sampsonas

Herazo-Maya

et al. 2023

Current Opinion in Pulmonary Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

Differential expression of PD-1/PD-L1 axis in mediastinal lymph nodes of experimental and human lung fibrosis

Cited by 1 publication

References 0 publications

Management of patients with idiopathic pulmonary fibrosis and lung cancer: challenges in clinical practice

Management of patients with idiopathic pulmonary fibrosis and lung cancer: challenges in clinical practice

Contact Info

Product

Resources

About